We investigated the changes in GH-IGF-I axis in non-obese diabetic 
INTRODUCTION
IDDM is accompanied by long-term complications, including nephropathy, retinopathy, neuropathy and advanced atherosclerosis (Deckert et al., 1978) . The appearance of these complications, mainly nephropathy, increases the relative mortality of IDDM patients by 100 times that of the background population (Borch-Johnsen et al., 1985) . Growth hormone (GH) and insulinlike growth factors (IGFs) may participate in the development of diabetic kidney disease (Flyvbjerg et al., 1992 (Flyvbjerg et al., , 1989 Bach and Jerums, 1990; Phillip et al., 1994; Werner et al., 1990) , as well as other diabetic complications (Holly et al., 1988; Houssay, 1936 The classical endocrine effect of pituitarysecreted GH is the induction of liver IGF-I production and secretion. This effect is mediated via activation of the specific GH receptor (GHR) , which is extensively distributed in many tissues (Chin et al., 1992) . Its binding to GH activates a signal transduction pathway (Cunningham et al., 1991) , which leads to increased transcription of several early response genes (Gronowski and Rotwein, 1994) . Therefore it is possible that GH exerts effects on target tissues which are independent of IGF-I. In addition, diabetic children and adolescents may not grow well (Murata et al., 1994; Phillips and Orawski, 1977) . This growth retardation may be due to GH resistance (English et al., 1993) .
Experimental diabetes in rats using streptozotocin (STZ) is characterized by suppressed circulating levels of GH (Tannenbaum, 1981) . This is contrary to what has been described in humans (Blankestijn et al., 1993; Press et al., 1984; Hayford et al., 1980) . In addition, typical diabetic glomerulosclerosis associated with increasing azotemia does not develop, even in longterm follow-up models. STZ may also induce tumoral growth in the kidney, and fl-cell regeneration may appear (Horton et al., 1997; Chieco et al., 1993) . In contrast, the non-obese diabetic (NOD)-mouse model may resemble human diabetic nephropathy more closely (Velasquez et al., 1990) . The NOD-mice develop hypoinsulinemia secondary to autoimmune destruction of pancreatic fl-cells at an age of between 100 and 200 days (Tochino, 1984) , in association with insulitis and autoantibody production (Wicker et al., 1986) . As in humans, NOD mice develop proteinuria and significant glomerular lesions, including a prompt increase in glomerular surface area and an increase in mesangial sclerosis (Doi et al., 1990) .
No data are available on serum GH levels in NOD mice and their influence on liver IGF-I secretion. In the present study we evaluated the changes in serum GH and IGF-I, and analyzed the expression and activity of liver and kidney GHR and GHBP in Frozen tissues in 4M guanidinium isothiocyahate were loaded on cesium chloride and total RNA was isolated following the methods as described elsewhere (Phillip et al., 1994 
Receptor Preparation
Receptor preparation was carried out as previously described (Tushina and Friesen, 1973) . Liver was homogenized in 0.25% sucrose solution, centrifuged at 10,000g for 10 minutes followed by further centrifugation of the supernatant at 100,000 g for 90 minutes, which yielded the microsomal pellet. The pellet was then resuspended in 25 mM Tris-HC1/10 mM MgC12 buffer (pH 7.4). The quantity of microsomal proteins was measured by the method of Lowry et al. (1951) , using human serum albumin as a standard. The microsomal fraction was frozen and thawed 3 times and then kept frozen until used for the binding studies (Bergeron et al., 1978 (Eshet et al., 1985 was also lower than controls (85.6 4-2% of control, P < 0.01) but higher than the 30d DM animals (21.7 4-0.61 vs. 18.3 4-0.82 grams; P < 0.01) (Fig. la) (Fig. lb) . Serum GH levels were elevated in the 30d DM group in comparison to controls (51 4-9 vs. 28 4-2 ng/ml respectively; p < 0.01) (Fig. 1) (Fig. lc) . Data on serum IGF-I levels have been previously described by us (Segev et al., 1997 (Fig. 2) . Renal GHR and GHBP mRNA levels showed complex changes in 2 and 3-week non-treated diabetic mice in comparison to controls (Fig. 3) . GHBP mRNA remained unchanged in these two time points. Renal GHR mRNA was not significantly decreased at two weeks of DM (77 4 Figure 2a , using a phosphorimager. The data are expressed as the percentage of age-matched non-diabetic controls, n 5 rats in each group. *p < 0.05 vs. control.
p-NS). GHR binding capacity remained low
and unchanged in the 30d DM + I group (Fig. 4) .
DISCUSSION
This study shows new evidence on the similarity of the NOD model to human IDDM: as in humans, increased circulating GH levels are found in these hyperglycemic mice, a change that is not modulated by insulin therapy. GH is usually secreted in a pulsatile fashion, and a single measurement of the serum GH may not properly reflect GH levels. However, in the control group GH has also been sampled in the same way. In addition, the decapitation procedure for blood sampling in our experiment has been shown to be a significant stimulus for GH secretion (Takahashi et al., 1971 (Esposito et al., 1996) . Recently Doublier et al. (1997) provided an additional evidence for the importance of a high GH-low IGF-I environment for the development of glomerulosclerosis: transgenic mice for IGFBP-1 that display such a hormonal combination develop glomerulosclerosis. Doi et al. (1990) (Solomon et al., 1990) . Thus, GHR and GHBP may be differentially regulated in IDDM.
Renal GH binding to kidney tissue is increased in diabetic rats (Marshall et al., 1991) . In addition, renal GHBP is upregulated in a model of long-term diabetes (Landau et al., 1998) . No change in renal GHR mRNA levels was seen in that model. Kidney IGF-I protein is accumulated in diabetic animals (Segev et al., 1997) together with an increase in kidney IGFBP-1. Given (Bornfelt et al., 1989) or in postreceptor mechanisms (Maes et al., 1986) . We show in this study that circulating IGF-I levels are decreased in diabetic mice. In a previous study (Segev et al., 1997) (Massa et al., 1993) . A decrease in serum GHBP was found in human patients with IDDM (Mercado et al., 1992) . Such reduced IGF-I secretion is associated with low hepatic GHR levels that also normalize during insulin treatment (Postel Vinay et al., 1982) .
A similar relationship between serum insulin levels and serum GHBP was also shown in humans (Kratzsch et al., 1996) . We show here that elevated serum GH and decreased serum IGF-I levels are associated with a decreased expression of liver GHR and GHBP mRNA and GH binding. Insulin treatment did not fully reverse these findings. Previous studies in rats have raised the possibility of a cross binding of hGH with the rat prolactin receptor (Postel Vinay and Desbuquois, 1977) 
